FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136733759> ?p ?o ?g. }

• W2136733759 endingPage "1953" @default.
• W2136733759 startingPage "1948" @default.
• W2136733759 abstract "BackgroundBiosimilars of filgrastim are in widespread clinical use in Europe. This phase III study compares biosimilar filgrastim (EP2006), with the US-licensed reference product, Neupogen®, in breast cancer patients receiving (neo)adjuvant myelosuppressive chemotherapy (TAC).Patients and methodsA total of 218 patients receiving 5 µg/kg/day filgrastim over six chemotherapy cycles were randomized 1:1:1:1 into four arms. Two arms received only one product (nonalternating), biosimilar or reference, and two arms (alternating) received alternating treatments during each cycle (biosimilar then reference or vice versa). The primary end point was duration of severe neutropenia (DSN) during cycle 1.ResultsThe baseline characteristics were balanced between the four treatment arms. Noninferiority of biosimilar versus the reference was demonstrated: DSN (days) in cycle 1 was 1.17 ± 1.11 (biosimilar, N = 101) and 1.20 ± 1.02 (reference, N = 103), 97.5% confidence interval lower boundary for the difference was -0.26 days (above the predefined limit of -1 day). No clinically meaningful differences were observed regarding any other efficacy parameter: incidence of febrile neutropenia (FN); hospitalization due to FN; incidence of infections; depth and time of absolute neutrophil count (ANC) nadir and time to ANC recovery during cycle 1 and across all cycles. The pattern and frequency of adverse events were similar across all treatments.ConclusionThis study demonstrates that biosimilar and the reference filgrastim are similar with no clinically meaningful differences regarding efficacy and safety in prevention of severe neutropenia. Biosimilar filgrastim could represent an important alternative to the reference product, potentially benefiting public health by increasing access to filgrastim treatment.Study numberNCT01519700." @default.
• W2136733759 created "2016-06-24" @default.
• W2136733759 creator A5004205253 @default.
• W2136733759 creator A5004944088 @default.
• W2136733759 creator A5014058084 @default.
• W2136733759 creator A5014196034 @default.
• W2136733759 creator A5020939803 @default.
• W2136733759 creator A5022667766 @default.
• W2136733759 creator A5027231412 @default.
• W2136733759 creator A5040771737 @default.
• W2136733759 creator A5044607777 @default.
• W2136733759 creator A5059110182 @default.
• W2136733759 creator A5065510776 @default.
• W2136733759 date "2015-09-01" @default.
• W2136733759 modified "2023-10-16" @default.
• W2136733759 title "Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy" @default.
• W2136733759 cites W1949811104 @default.
• W2136733759 cites W1969787209 @default.
• W2136733759 cites W1969840975 @default.
• W2136733759 cites W2020476117 @default.
• W2136733759 cites W2035763718 @default.
• W2136733759 cites W2037514943 @default.
• W2136733759 cites W2050597642 @default.
• W2136733759 cites W2087926562 @default.
• W2136733759 cites W2100082529 @default.
• W2136733759 cites W2115170812 @default.
• W2136733759 cites W2122038099 @default.
• W2136733759 cites W2128953593 @default.
• W2136733759 cites W2129812004 @default.
• W2136733759 cites W2133042104 @default.
• W2136733759 cites W2169403306 @default.
• W2136733759 doi "https://doi.org/10.1093/annonc/mdv281" @default.
• W2136733759 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4551159" @default.
• W2136733759 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26122726" @default.
• W2136733759 hasPublicationYear "2015" @default.
• W2136733759 type Work @default.
• W2136733759 sameAs 2136733759 @default.
• W2136733759 citedByCount "65" @default.
• W2136733759 countsByYear W21367337592014 @default.
• W2136733759 countsByYear W21367337592016 @default.
• W2136733759 countsByYear W21367337592017 @default.
• W2136733759 countsByYear W21367337592018 @default.
• W2136733759 countsByYear W21367337592019 @default.
• W2136733759 countsByYear W21367337592020 @default.
• W2136733759 countsByYear W21367337592021 @default.
• W2136733759 countsByYear W21367337592022 @default.
• W2136733759 countsByYear W21367337592023 @default.
• W2136733759 crossrefType "journal-article" @default.
• W2136733759 hasAuthorship W2136733759A5004205253 @default.
• W2136733759 hasAuthorship W2136733759A5004944088 @default.
• W2136733759 hasAuthorship W2136733759A5014058084 @default.
• W2136733759 hasAuthorship W2136733759A5014196034 @default.
• W2136733759 hasAuthorship W2136733759A5020939803 @default.
• W2136733759 hasAuthorship W2136733759A5022667766 @default.
• W2136733759 hasAuthorship W2136733759A5027231412 @default.
• W2136733759 hasAuthorship W2136733759A5040771737 @default.
• W2136733759 hasAuthorship W2136733759A5044607777 @default.
• W2136733759 hasAuthorship W2136733759A5059110182 @default.
• W2136733759 hasAuthorship W2136733759A5065510776 @default.
• W2136733759 hasBestOaLocation W21367337591 @default.
• W2136733759 hasConcept C126322002 @default.
• W2136733759 hasConcept C143998085 @default.
• W2136733759 hasConcept C197934379 @default.
• W2136733759 hasConcept C2776694085 @default.
• W2136733759 hasConcept C2777063308 @default.
• W2136733759 hasConcept C2778850193 @default.
• W2136733759 hasConcept C2779171977 @default.
• W2136733759 hasConcept C59491497 @default.
• W2136733759 hasConcept C71924100 @default.
• W2136733759 hasConcept C74133956 @default.
• W2136733759 hasConceptScore W2136733759C126322002 @default.
• W2136733759 hasConceptScore W2136733759C143998085 @default.
• W2136733759 hasConceptScore W2136733759C197934379 @default.
• W2136733759 hasConceptScore W2136733759C2776694085 @default.
• W2136733759 hasConceptScore W2136733759C2777063308 @default.
• W2136733759 hasConceptScore W2136733759C2778850193 @default.
• W2136733759 hasConceptScore W2136733759C2779171977 @default.
• W2136733759 hasConceptScore W2136733759C59491497 @default.
• W2136733759 hasConceptScore W2136733759C71924100 @default.
• W2136733759 hasConceptScore W2136733759C74133956 @default.
• W2136733759 hasIssue "9" @default.
• W2136733759 hasLocation W21367337591 @default.
• W2136733759 hasLocation W21367337592 @default.
• W2136733759 hasLocation W21367337593 @default.
• W2136733759 hasOpenAccess W2136733759 @default.
• W2136733759 hasPrimaryLocation W21367337591 @default.
• W2136733759 hasRelatedWork W2117609882 @default.
• W2136733759 hasRelatedWork W2252900637 @default.
• W2136733759 hasRelatedWork W2398255791 @default.
• W2136733759 hasRelatedWork W2553688676 @default.
• W2136733759 hasRelatedWork W2583990994 @default.
• W2136733759 hasRelatedWork W2732187261 @default.
• W2136733759 hasRelatedWork W2784130388 @default.
• W2136733759 hasRelatedWork W2899146514 @default.
• W2136733759 hasRelatedWork W3010100147 @default.
• W2136733759 hasRelatedWork W3207612165 @default.
• W2136733759 hasVolume "26" @default.
• W2136733759 isParatext "false" @default.

• next